- Home
- IONR vs DRUG Comparison
IONR vs DRUG Comparison
Compare IONR & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONR
- DRUG
- Stock Information
- Founded
- IONR 2001
- DRUG 2019
- Country
- IONR Australia
- DRUG United States
- Employees
- IONR N/A
- DRUG N/A
- Industry
- IONR
- DRUG Pharmaceuticals and Biotechnology
- Sector
- IONR
- DRUG Health Care
- Exchange
- IONR Nasdaq
- DRUG Nasdaq
- Market Cap
- IONR 319.2M
- DRUG 260.6M
- IPO Year
- IONR N/A
- DRUG N/A
- Fundamental
- Price
- IONR $5.23
- DRUG $36.78
- Analyst Decision
- IONR
- DRUG Strong Buy
- Analyst Count
- IONR 0
- DRUG 3
- Target Price
- IONR N/A
- DRUG $80.00
- AVG Volume (30 Days)
- IONR 51.6K
- DRUG 79.3K
- Earning Date
- IONR 01-01-0001
- DRUG 12-31-2024
- Dividend Yield
- IONR N/A
- DRUG N/A
- EPS Growth
- IONR N/A
- DRUG N/A
- EPS
- IONR N/A
- DRUG N/A
- Revenue
- IONR N/A
- DRUG N/A
- Revenue This Year
- IONR N/A
- DRUG N/A
- Revenue Next Year
- IONR N/A
- DRUG N/A
- P/E Ratio
- IONR N/A
- DRUG N/A
- Revenue Growth
- IONR N/A
- DRUG N/A
- 52 Week Low
- IONR $2.90
- DRUG $0.93
- 52 Week High
- IONR $9.35
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- IONR 66.61
- DRUG 46.15
- Support Level
- IONR $4.05
- DRUG $35.02
- Resistance Level
- IONR $4.58
- DRUG $38.00
- Average True Range (ATR)
- IONR 0.41
- DRUG 3.09
- MACD
- IONR 0.14
- DRUG -0.37
- Stochastic Oscillator
- IONR 86.78
- DRUG 30.44
About IONR ioneer Ltd
Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S.-based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.